MTOR and osteoporosis: According to immunosuppressive therapies, the prevalence of osteoporosis in KTRs treated with tacrolimus, cyclosporine, and mTOR inhibitors (including sirolimus and everolimus) was 14% (95% CI 9–19), 17% (95% CI 9–25), and 22% (95% CI 10–34), respectively.